Atlas Trials

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Clinical trial NCT04418154 · UNKNOWN

Trial details

NCT number
NCT04418154
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2020-06-09
Primary completion
2022-09-28
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.